Cybin’s Helus Pharma CEO to speak Sept. 14 in NYC
Cybin Inc.’s Helus Pharma brand will showcase its late-stage NSA mental health pipeline in a fireside chat at a major H.C. Wainwright investor conference.
Rhea-AI Filing Summary
Cybin Inc. (Helus Pharma) reported that its commercial operating name, Helus Pharma (Nasdaq/Cboe CA: HELP), will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York City, with CEO Michael Halstead speaking on September 14, 2026 at 9:00 a.m. EDT via live webcast. A replay will be available on the company’s investor relations website.
The company describes itself as a clinical-stage pharmaceutical developer of proprietary novel serotonergic agonists (NSAs) targeting mental health conditions. Its lead candidate, HLP003, is in Phase 3 development as an adjunctive treatment for major depressive disorder and has received U.S. FDA Breakthrough Therapy Designation, while HLP004 is in Phase 2 for generalized anxiety disorder. Helus Pharma also highlights an extensive NSA research portfolio and operations across Canada, the United States, the United Kingdom, and Ireland, while cautioning that all product claims remain subject to further regulatory review and clinical validation.
Positive
- None.
Negative
- None.
Key Figures
Conference fireside chat time: 9:00 a.m. EDT
Conference dates: September 14–16, 2026
HLP003 development stage: Phase 3
+2 more
5 metrics
Conference fireside chat time
9:00 a.m. EDT
Scheduled time for Helus Pharma CEO’s fireside chat on September 14, 2026
Conference dates
September 14–16, 2026
H.C. Wainwright 28th Annual Global Investment Conference in New York City
HLP003 development stage
Phase 3
Adjunctive treatment for major depressive disorder with FDA Breakthrough Therapy Designation
HLP004 development stage
Phase 2
Clinical development for generalized anxiety disorder
Breakthrough Therapy Designation
Granted for HLP003
U.S. FDA designation for adjunctive treatment of major depressive disorder
Key Terms
foreign private issuer, novel serotonergic agonists, Breakthrough Therapy Designation, major depressive disorder, +2 more
6 terms
foreign private issuer regulatory
"Form 6-K report of foreign private issuer pursuant to Rule 13a-16"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
novel serotonergic agonists medical
"developing novel serotonergic agonists (“NSAs”)"
Breakthrough Therapy Designation regulatory
"HLP003 ... has received Breakthrough Therapy Designation"
A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.
major depressive disorder medical
"adjunctive treatment of major depressive disorder"
A clinical condition characterized by persistent, severe low mood, loss of interest in daily activities, and reduced ability to function at work or home, lasting weeks or longer. It matters to investors because it drives demand for treatments and mental health services, affects workforce productivity and absenteeism, influences health-care and insurance costs, and shapes risks and opportunities for companies developing drugs, therapies or workplace programs—like a long-lasting storm that lowers economic output.
generalized anxiety disorder medical
"proprietary NSA in Phase 2 for generalized anxiety disorder"
Generalized anxiety disorder is a chronic mental health condition marked by persistent, excessive worry about everyday things that is hard to control and interferes with daily life. Think of it like a smoke alarm that stays on for weeks or months, making work, decision-making and productivity harder; for investors it matters because it drives demand for treatments, affects workforce performance and can influence regulatory scrutiny, clinical trial design and healthcare spending.
forward-looking statements regulatory
"Certain statements in this news release ... are forward-looking statements"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
What did Cybin Inc. (HELP) announce in this Form 6-K?
Cybin Inc., operating commercially as Helus Pharma, announced that CEO Michael Halstead will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York City, with a live webcast and replay available to investors.
When will Helus Pharma’s (HELP) conference fireside chat take place?
The Helus Pharma fireside chat is scheduled for Monday, September 14, 2026 at 9:00 a.m. EDT during the H.C. Wainwright 28th Annual Global Investment Conference, which runs from September 14–16, 2026 in New York City.
What are the lead drug candidates highlighted by Helus Pharma (HELP)?
Helus Pharma highlights HLP003, a proprietary NSA in Phase 3 development for adjunctive treatment of major depressive disorder with FDA Breakthrough Therapy Designation, and HLP004, a proprietary NSA in Phase 2 development for generalized anxiety disorder.
How does Cybin Inc. describe Helus Pharma’s business focus?
Helus Pharma is described as a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists designed to activate serotonin pathways believed to promote neuroplasticity, aiming to address unmet needs in depression, anxiety, and other mental health conditions.
In which regions does Helus Pharma (HELP) operate?
Helus Pharma states that it operates in Canada, the United States, the United Kingdom, and Ireland, supporting its clinical and research activities in novel serotonergic agonists for mental health indications.
What regulatory status does HLP003 have according to Helus Pharma?
Helus Pharma reports that HLP003, its Phase 3 NSA for adjunctive treatment of major depressive disorder, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, signaling regulatory recognition of its potential based on existing data.
What cautions does Helus Pharma (HELP) provide about its NSA programs?
Helus Pharma states that regulators such as the U.S. FDA and Health Canada have not evaluated claims regarding its NSAs or programs, that efficacy is unconfirmed, and that rigorous research and clinical trials and regulatory approvals are needed before commercialization.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September, 2026.
Commission File Number: 001-40673
Cybin Inc.
(Exact Name of Registrant as Specified in Charter)
100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F □ Form 40-F ⊠
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CYBIN INC. | ||||||||||||||
| (Registrant) | ||||||||||||||
| Date: | September 9, 2026 | By: | /s/ Greg Cavers | |||||||||||
| Name: | Greg Cavers | |||||||||||||
| Title: | Chief Financial Officer | |||||||||||||
EXHIBIT INDEX
| 99.1 | News Release dated September 9, 2026 | ||||
Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York
CEO Michael Halstead to participate in a fireside chat on Monday, September 14, 2026 at 9:00 a.m. EDT.
NEW YORK & TORONTO – September 9, 2026 – Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced that Michael Halstead, Helus Pharma’s Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York City taking place September 14-16, 2026.
The fireside chat will be webcast live on Monday, September 14, 2026 at 9:00 a.m. EDT.
To register for the webcast, click here. A replay will be available on the Events & Presentations page of Helus Pharma’s investor relations website.
About Helus Pharma
Helus Pharma™, the commercial operating name of Cybin Inc., is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs, synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The Company’s proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.
With class leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.
The Company operates in Canada, the United States, the United Kingdom, and Ireland. For Company updates and to learn more about Helus Pharma, visit www.helus.com or follow the team on X, LinkedIn, YouTube and Instagram. Helus Pharma™ is a trademark of Helus Pharma Corp.
Cautionary Notes and Forward-Looking Statements
Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “potential”, “possible”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company's anticipated participation in the H.C. Wainwright 28th Annual Global Investment Conference; and plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions.
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the NSA market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three months ended June 30, 2026, and the Company’s annual information form for the year ended March 31, 2026, which are available under the Company's profile on SEDAR+ at www.sedarplus.ca/ and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov/edgar. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
The Company makes no medical, treatment or health benefit claims about the Company’s proposed products. The U.S Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding NSAs or HLP003, HLP004 and other programs of the Company. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of NSAs, HLP003, HLP004 or other programs of the Company can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Helus Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.
Neither Cboe Canada, nor the Nasdaq Global Market stock exchange, have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.
Investor Contact:
Matthew Beck
astr partners
Managing Partner
(917) 415-1750
Matthew.beck@astrpartners.com
Gabriel Fahel
Chief Legal Officer
Helus Pharma
1-866-292-4601
irteam@helus.com – or – media@helus.com
Media Contact:
Victoria Verdeja
RXMD
Public Relations Director
(212) 537-9495
Vverdeja@rxmedyn.com